{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AMN107&page=2",
    "query": {
      "intervention": "AMN107",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AMN107&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-15T14:58:54.896Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00702403",
      "title": "Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Accelerated Phase Chronic Myelogenous Leukemia",
        "Adult Acute Lymphoblastic Leukemia in Remission",
        "Blastic Phase Chronic Myelogenous Leukemia",
        "Childhood Acute Lymphoblastic Leukemia in Remission",
        "Childhood Chronic Myelogenous Leukemia",
        "Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Chronic Phase Chronic Myelogenous Leukemia",
        "Philadelphia Positive Adult Acute Lymphoblastic Leukemia",
        "Philadelphia Positive Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Relapsing Chronic Myelogenous Leukemia",
        "Untreated Adult Acute Lymphoblastic Leukemia",
        "Untreated Childhood Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "nilotinib",
          "type": "DRUG"
        },
        {
          "name": "imatinib mesylate",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 40,
      "start_date": "2008-08-14",
      "completion_date": "2013-12-01",
      "has_results": true,
      "last_update_posted_date": "2017-08-10",
      "last_synced_at": "2026-09-15T14:58:54.896Z",
      "location_count": 5,
      "location_summary": "Stanford, California • Tampa, Florida • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00702403"
    },
    {
      "nct_id": "NCT01744665",
      "title": "A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "CML"
      ],
      "interventions": [
        {
          "name": "nilotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2013-08-12",
      "completion_date": "2018-09-29",
      "has_results": true,
      "last_update_posted_date": "2020-03-10",
      "last_synced_at": "2026-09-15T14:58:54.896Z",
      "location_count": 54,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 44 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01744665"
    },
    {
      "nct_id": "NCT00732888",
      "title": "Effect of Calcium on Tasigna Pharmacokinetics (PK) in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Nilotinib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "calcium carbonate",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Jan Beumer",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2008-11",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2013-12-18",
      "last_synced_at": "2026-09-15T14:58:54.896Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00732888"
    },
    {
      "nct_id": "NCT00644878",
      "title": "Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myelogenous Leukemia - Chronic Phase"
      ],
      "interventions": [
        {
          "name": "Nilotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2008-10",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2021-08-18",
      "last_synced_at": "2026-09-15T14:58:54.896Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Augusta, Georgia • Beech Grove, Indiana + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Beech Grove",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00644878"
    },
    {
      "nct_id": "NCT01784068",
      "title": "Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "Nilotinib followed by treatment-free",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 215,
      "start_date": "2013-03-19",
      "completion_date": "2025-01-23",
      "has_results": true,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-09-15T14:58:54.896Z",
      "location_count": 10,
      "location_summary": "Fort Myers, Florida • Miami Lakes, Florida • Tampa, Florida + 7 more",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01784068"
    },
    {
      "nct_id": "NCT04205903",
      "title": "Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anatomic Stage I Breast Cancer AJCC v8",
        "Anatomic Stage IA Breast Cancer AJCC v8",
        "Anatomic Stage IB Breast Cancer AJCC v8",
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage IIA Breast Cancer AJCC v8",
        "Anatomic Stage IIB Breast Cancer AJCC v8",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "Anatomic Stage IIIB Breast Cancer AJCC v8",
        "Anatomic Stage IIIC Breast Cancer AJCC v8",
        "Prognostic Stage I Breast Cancer AJCC v8",
        "Prognostic Stage IA Breast Cancer AJCC v8",
        "Prognostic Stage IB Breast Cancer AJCC v8",
        "Prognostic Stage II Breast Cancer AJCC v8",
        "Prognostic Stage IIA Breast Cancer AJCC v8",
        "Prognostic Stage IIB Breast Cancer AJCC v8",
        "Prognostic Stage III Breast Cancer AJCC v8",
        "Prognostic Stage IIIA Breast Cancer AJCC v8",
        "Prognostic Stage IIIB Breast Cancer AJCC v8",
        "Prognostic Stage IIIC Breast Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Nilotinib",
          "type": "DRUG"
        },
        {
          "name": "Nilotinib Hydrochloride Monohydrate",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2020-12-11",
      "completion_date": "2024-12-18",
      "has_results": true,
      "last_update_posted_date": "2025-06-29",
      "last_synced_at": "2026-09-15T14:58:54.896Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04205903"
    },
    {
      "nct_id": "NCT00980018",
      "title": "An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "Nilotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2009-12",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2021-07-01",
      "last_synced_at": "2026-09-15T14:58:54.896Z",
      "location_count": 19,
      "location_summary": "Fayetteville, Arkansas • Little Rock, Arkansas • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Poway",
          "state": "California"
        },
        {
          "city": "Greenwood Village",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00980018"
    },
    {
      "nct_id": "NCT00135005",
      "title": "Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastrointestinal Stromal Tumors"
      ],
      "interventions": [
        {
          "name": "AMN107, STI571",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2005-08",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2020-12-08",
      "last_synced_at": "2026-09-15T14:58:54.896Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00135005"
    },
    {
      "nct_id": "NCT05554341",
      "title": "Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Malignant Solid Neoplasm",
        "Refractory Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nilotinib Hydrochloride Monohydrate",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2023-07-14",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-09-15T14:58:54.896Z",
      "location_count": 124,
      "location_summary": "Birmingham, Alabama • Kingman, Arizona • Palo Alto, California + 101 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Kingman",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05554341"
    },
    {
      "nct_id": "NCT01179737",
      "title": "Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Nilotinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo to nilotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2010-07",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2014-05-01",
      "last_synced_at": "2026-09-15T14:58:54.896Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Chapel Hill, North Carolina + 2 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01179737"
    }
  ]
}